Neuroinvasion of α-synuclein prionoids after intraperitoneal and intraglossal inoculation

Journal of Virology

Volumn 90, Issue 20, 2016, Pages 9182-9193

  Breid, Sara ^a   Bernis, Maria E ^a   Babila, Julius T ^a   Garza, Maria C ^b,c   Wille, Holger ^b   Tamgüney, Gültekin ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSIDAD DE ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; FIREFLY LUCIFERASE; PHOSPHATE BUFFERED SALINE; PROTEIN P62; UBIQUITIN; PRION PROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN LEVEL; CONTROLLED STUDY; FEMALE; GLIOSIS; INCUBATION TIME; INOCULATION; MALE; MOUSE; NERVE FIBER; NEUROPATHOLOGY; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MISFOLDING; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SPINAL CORD; ANIMAL; CENTRAL NERVOUS SYSTEM; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CENTRAL NERVOUS SYSTEM; INJECTIONS, INTRAPERITONEAL; MICE; PARALYSIS; PRION PROTEINS; RECOMBINANT PROTEINS;

EID: 84990041194     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01399-16     Document Type: Article

References (53)

1. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. 1998. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251:205-208. http://dx.doi.org/10.1016/S0304-3940(98)00504-7.
2. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. 1998. Alphasynuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249:180-182. http://dx.doi.org/10.1016/S0304-3940(98)00407-8.
3. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95:6469-6473. http://dx.doi.org/10.1073/pnas.95.11.6469.
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047. http://dx.doi.org/10.1126/science.276.5321.2045.
5. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. Alphasynuclein locus triplication causes Parkinson's disease. Science 302:841. http://dx.doi.org/10.1126/science.1090278.
6. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A. 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169. http://dx.doi.org/10.1016/S0140-6736(04)17103-1.
7. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A. 2004. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364:1169-1171. http://dx.doi.org/10.1016/S0140-6736(04)17104-3.
8. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. 2003 Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211. http://dx.doi.org/10.1016/S0197-4580(02)00065-9.
9. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG. 2012. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol 22:745-756. http://dx.doi.org/10.1111/j.1750-3639.2012.00585.x.
10. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P. 2008. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14:501-503 http://dx.doi.org/10.1038/nm1746.
11. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. 2008. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14:504-506. http://dx.doi.org/10.1038/nm1747.
12. Conway KA, Harper JD, Lansbury PT. 1998. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318-1320. http://dx.doi.org/10.1038/3311.
13. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. 2009. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106:13010-13015. http://dx.doi.org/10.1073/pnas.0903691106.
14. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM. 2011. Exogenous alphasynuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57-71. http://dx.doi.org/10.1016/j.neuron.2011.08.033.
15. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. 2012. Pathological alpha-synuclein transmission initiates Parkinsonlike neurodegeneration in nontransgenic mice. Science 338:949-953. http://dx.doi.org/10.1126/science.1227157.
16. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L, Legastelois S, Baron T. 2012. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33:2225-2228. http://dx.doi.org/10.1016/j.neurobiolaging.2011.06.022.
17. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, Dearmond SJ, Prusiner SB. 2013. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad SciUSA110:19555-19560. http://dx.doi.org/10.1073/pnas.1318268110.
18. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M. 2013. Prion-like spreading of pathological alpha-synuclein in brain. Brain 136:1128-1138. http://dx.doi.org/10.1093/brain/awt037.
19. Rey NL, Petit GH, Bousset L, Melki R, Brundin P. 2013. Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 126:555-573. http://dx.doi.org/10.1007/s00401-013-1160-3.
20. Bernis ME, Babila JT, Breid S, Wusten KA, Wullner U, Tamguney G. 2015 Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun 3:75. http://dx.doi.org/10.1186/s40478-015-0254-7.
21. Tamgüney G, Richt JA, Hamir AN, Greenlee JJ, Miller MW, Wolfe LL, Sirochman TM, Young AJ, Glidden DV, Johnson NL, Giles K, DeArmond SJ, Prusiner SB. 2012. Salivary prions in sheep and deer. Prion 6:52-61. http://dx.doi.org/10.4161/pri.6.1.16984.
22. Tamgüney G, Miller MW, Wolfe LL, Sirochman TM, Glidden DV, Palmer C, Lemus A, DeArmond SJ, Prusiner SB. 2009. Asymptomatic deer excrete infectious prions in faeces. Nature 461:529-532. http://dx.doi.org/10.1038/nature08289.
23. Aguzzi A. 2009. Cell biology: beyond the prion principle. Nature 459: 924-925. http://dx.doi.org/10.1038/459924a.
24. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, Doey LJ, Lantos P. 1997. The same prion strain causes vCJD and BSE. Nature 389:448-450, 526. http://dx.doi.org/10.1038/38925.
25. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. 2006. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 91:221-230. http://dx.doi.org/10.1111/j.1423-0410.2006.00833.x.
26. Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, Will RG, Ladogana A, Pocchiari M, Leschek EW, Schonberger LB. 2012. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 18: 901-907. http://dx.doi.org/10.3201/eid1806.120116.
27. Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J, Launchbury F, Linehan J, Richard-Loendt A, Walker AS, Rudge P, Collinge J, Brandner S. 2015. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 525:247-250 http://dx.doi.org/10.1038/nature15369.
28. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002 Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521-533. http://dx.doi.org/10.1016/S0896-6273(02)00682-7.
29. Zhu L, Ramboz S, Hewitt D, Boring L, Grass DS, Purchio AF. 2004. Non-invasive imaging of GFAP expression after neuronal damage in mice. Neurosci Lett 367:210-212. http://dx.doi.org/10.1016/j.neulet.2004.06.020.
30. Bartz JC, Kincaid AE, Bessen RA. 2003. Rapid prion neuroinvasion following tongue infection. J Virol 77:583-591. http://dx.doi.org/10.1128/JVI.77.1.583-591.2003.
31. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. 2002. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160-164.
32. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, Mayer RJ. 1988. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 155:9-15. http://dx.doi.org/10.1002/path.1711550105.
33. Kuusisto E, Salminen A, Alafuzoff I. 2001. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12:2085-2090. http://dx.doi.org/10.1097/00001756-200107200-00009.
34. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. 2010 Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330:980-982. http://dx.doi.org/10.1126/science.1194516.
35. Clavaguera F, Hench J, Lavenir I, Schweighauser G, Frank S, Goedert M, Tolnay M. 2014. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol 127:299-301 http://dx.doi.org/10.1007/s00401-013-1231-5.
36. Siso S, Gonzalez L, Jeffrey M. 2010. Neuroinvasion in prion diseases: the roles of ascending neural infection and blood dissemination. Interdiscip Perspect Infect Dis 2010:747892. http://dx.doi.org/10.1155/2010/747892.
37. Braak H, de Vos RA, Bohl J, Del Tredici K. 2006. Gastric alphasynuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396:67-72. http://dx.doi.org/10.1016/j.neulet.2005.11.012.
38. Hawkes CH, Del Tredici K, Braak H. 2007. Parkinson's disease: a dualhit hypothesis. Neuropathol Appl Neurobiol 33:599-614. http://dx.doi.org/10.1111/j.1365-2990.2007.00874.x.
39. Ulusoy A, Rusconi R, Perez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, Di Monte DA. 2013. Caudo-rostral brain spreading of alpha-synuclein through vagal connections. EMBO Mol Med 5:1051-1059 http://dx.doi.org/10.1002/emmm.201201823.
40. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjorklund T, Wang ZY, Roybon L, Melki R, Li JY. 2014. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 128:805-820. http://dx.doi.org/10.1007/s00401-014-1343-6.
41. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, Borchelt DR, Golde TE, Giasson BI. 2014. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A 111:10732-10737. http://dx.doi.org/10.1073/pnas.1321785111.
42. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V. 2015. Alphasynuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522:340-344. http://dx.doi.org/10.1038/nature14547.
43. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White CL, III, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, Arizona Parkinson's Disease Consortium. 2010. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119:689-702. http://dx.doi.org/10.1007/s00401-010-0664-3.
44. Cersosimo MG, Benarroch EE. 2012. Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis 46:559-564. http://dx.doi.org/10.1016/j.nbd.2011.10.014.
45. Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ, Marti MJ, Hernandez I, Valldeoriola F, Rene R, Ribalta T. 2014. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 29:1010-1018. http://dx.doi.org/10.1002/mds.25776.
46. Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C. 2014. Accumulation of alphasynuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol 127:235-241. http://dx.doi.org/10.1007/s00401-013-1214-6.
47. Zange L, Noack C, Hahn K, Stenzel W, Lipp A. 2015. Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain 138:2310-2321. http://dx.doi.org/10.1093/brain/awv138.
48. Bruce ME, McConnell I, Will RG, Ironside JW. 2001. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 358:208-209. http://dx.doi.org/10.1016/S0140-6736(01)05411-3.
49. McCulloch L, Brown KL, Bradford BM, Hopkins J, Bailey M, Rajewsky K, Manson JC, Mabbott NA. 2011. Follicular dendritic cell-specific prion protein (PrP) expression alone is sufficient to sustain prion infection in the spleen. PLoS Pathog 7:e1002402. http://dx.doi.org/10.1371/journal.ppat.1002402.
50. Glatzel M, Abela E, Maissen M, Aguzzi A. 2003. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 349: 1812-1820. http://dx.doi.org/10.1056/NEJMoa030351.
51. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ. 2008. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5:55-59 http://dx.doi.org/10.1159/000112832.
52. Rudge P, Jaunmuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J, Norsworthy P, Hummerich H, Druyeh R, Wadsworth JD, Brandner S, Hyare H, Mead S, Collinge J. 2015. Iatrogenic CJD due to pituitaryderived growth hormone with genetically determined incubation times of up to 40 years. Brain 138:3386-3399. http://dx.doi.org/10.1093/brain/awv235.
53. Frontzek K, Lutz MI, Aguzzi A, Kovacs GG, Budka H. 2016. Amyloidbeta pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med Wkly 146: w14287. http://dx.doi.org/10.4414/smw.2016.14287.